UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Pathology | tumors | Hospitals | Reviews | Safety engineering | survival | Mutation | intervention | surgery | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Recurrence | Prospective Studies | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Benzamides | Antimitotic agents | Arson | Antineoplastic agents | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 16, pp. 3852 - 3861
Dasatinib | Imatinib | Blast crisis | Chronic myeloid leukemia | Drug resistance | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Thiazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Thiazoles - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Adolescent | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Aged | Benzamides | Blast Crisis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Care and treatment | Patient outcomes | Dosage and administration | Research | Index Medicus | Abridged Index Medicus | imatinib | chronic myeloid leukemia | dasatinib | drug resistance | blast crisis
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5175 - 5181
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Bone Marrow Transplantation | Adult | Female | Child | Philadelphia Chromosome | Pyrimidines - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Imatinib Mesylate | Piperazines - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Adolescent | Pyrimidines - adverse effects | Benzamides | Index Medicus | Original Reports | Hema5 | Bios3 | Pedi2
Journal Article
Cancer, ISSN 0008-543X, 09/2009, Volume 115, Issue 18, pp. 4136 - 4147
Dasatinib | Imatinib | Chronic myeloid leukemia | Drug resistance | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Drug Resistance, Neoplasm | Thiazoles - therapeutic use | Withholding Treatment | Imatinib Mesylate | Piperazines - adverse effects | Thiazoles - adverse effects | Cross-Over Studies | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Benzamides | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus | imatinib | chronic myeloid leukemia | dasatinib | drug resistance
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1175 - 1182
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastrointestinal Stromal Tumors - enzymology | Piperazines - administration & dosage | Prospective Studies | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Indoles - administration & dosage | Benzamides - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Female | Gastrointestinal Stromal Tumors - mortality | Benzamides - adverse effects | Republic of Korea | Double-Blind Method | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - adverse effects | Aged | Antimitotic agents | Clinical trials | Product development | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Thiazoles - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Neutropenia - chemically induced | Dasatinib | Piperazines | Pyrimidines - administration & dosage | Genotype | Imatinib Mesylate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Product/Service Evaluations | Chronic myeloid leukemia | Drug therapy | Bone marrow | Kinases | Leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 12/2007, Volume 110, Issue 12, pp. 4064 - 4072
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Protein Kinase Inhibitors - pharmacokinetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Humans | Risk Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Organic Cation Transporter 1 - metabolism | Imatinib Mesylate | Remission Induction | Dose-Response Relationship, Drug | Time Factors | Pyrimidines - pharmacokinetics | Adult | Female | Benzamides | Piperazines - pharmacokinetics | Cohort Studies | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 10/2010, Volume 21, Issue 10, pp. 1990 - 1998
gastrointestinal stromal tumors | imatinib | GIST | everolimus (RAD001) | Everolimus (RAD001) | Gastrointestinal stromal tumors | Imatinib | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Piperazines - administration & dosage | Sirolimus - analogs & derivatives | Pyrimidines - administration & dosage | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Survival Rate | Treatment Outcome | Imatinib Mesylate | Neoplasm Recurrence, Local - pathology | Sirolimus - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Adult | Female | Aged | Benzamides | Neoplasm Staging | Everolimus | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | Index Medicus | Abridged Index Medicus | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article